Cabaletta Bio (NASDAQ:CABA) Given “Outperform” Rating at William Blair

William Blair restated their outperform rating on shares of Cabaletta Bio (NASDAQ:CABA) in a report released on Monday,RTT News reports.

Several other equities research analysts have also recently weighed in on CABA. Wells Fargo & Company decreased their price objective on shares of Cabaletta Bio from $20.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. Evercore ISI decreased their price target on Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Cabaletta Bio in a research note on Friday, November 15th. Finally, UBS Group initiated coverage on Cabaletta Bio in a research note on Thursday, October 10th. They set a “buy” rating and a $10.00 target price for the company. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cabaletta Bio has an average rating of “Buy” and an average target price of $27.30.

Cabaletta Bio Price Performance

Shares of CABA stock opened at $1.87 on Monday. Cabaletta Bio has a one year low of $1.76 and a one year high of $26.35. The business’s 50 day simple moving average is $4.07 and its 200 day simple moving average is $6.66. The stock has a market capitalization of $91.41 million, a PE ratio of -0.87 and a beta of 2.42.

Hedge Funds Weigh In On Cabaletta Bio

A number of institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Cabaletta Bio during the 3rd quarter valued at $32,000. Point72 DIFC Ltd acquired a new position in shares of Cabaletta Bio during the third quarter valued at about $33,000. China Universal Asset Management Co. Ltd. increased its position in shares of Cabaletta Bio by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock worth $44,000 after acquiring an additional 3,724 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Cabaletta Bio in the 3rd quarter worth about $67,000. Finally, GSA Capital Partners LLP bought a new position in Cabaletta Bio in the 3rd quarter valued at about $127,000.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.